Sources | Names Used |
---|---|
CTRPv2 | doxorubicin:navitoclax (2:1 mol/mol) |
PharmacoGx | doxorubicin:navitoclax (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | YIF1A | CTRPv2 | pan-cancer | AAC | -0.16 | 3e-06 |
mRNA | DBR1 | CTRPv2 | pan-cancer | AAC | 0.15 | 3e-06 |
mRNA | MTA2 | CTRPv2 | pan-cancer | AAC | 0.16 | 3e-06 |
mRNA | BCAR3 | CTRPv2 | pan-cancer | AAC | -0.17 | 3e-06 |
mRNA | PRPF39 | CTRPv2 | pan-cancer | AAC | 0.15 | 3e-06 |
mRNA | PHLDA1 | CTRPv2 | pan-cancer | AAC | -0.17 | 3e-06 |
mRNA | ARID2 | CTRPv2 | pan-cancer | AAC | 0.16 | 3e-06 |
mRNA | SV2A | CTRPv2 | pan-cancer | AAC | 0.16 | 3e-06 |
mRNA | PTOV1 | CTRPv2 | pan-cancer | AAC | 0.15 | 3e-06 |
mRNA | CTXN1 | CTRPv2 | pan-cancer | AAC | 0.16 | 3e-06 |